Terzi Demirsoy Esra, Birtas Atesoglu Elif, Eren Necmi, Gedük Ayfer, Mehtap Ozgur, Tarkun Pınar, Hacıhanefioğlu Abdullah
Department of Hematology, Kocaeli University School of Medicine, Kocaeli, Turkey.
Department of Nephrology, Kocaeli University School of Medicine, Kocaeli, Turkey.
Tumori. 2019 Dec;105(6):NP24-NP27. doi: 10.1177/0300891618793817. Epub 2018 Dec 23.
Tumor lysis syndrome (TLS) is a potentially fatal complication of cancer therapy characterized by severe electrolyte and metabolic abnormalities such as hyperphosphatemia, hyperkalemia, and hypocalcaemia. TLS usually occurs in aggressive hematologic malignancies such as Burkitt lymphoma and acute leukemia. TLS has rarely been observed in multiple myeloma (MM).
We present 2 patients with relapsed MM who developed TLS after the first cycle of carfilzomib treatment.
Carfilzomib is a next-generation proteasome inhibitor with proven efficacy in relapsed/refractory MM. Recently, increasing frequency of TLS has been reported in MM, especially after treatment with proteasome inhibitors. The potential complications of TLS should be considered especially during the first cycle of carfilzomib treatment.
肿瘤溶解综合征（TLS）是癌症治疗中一种潜在致命的并发症，其特征为严重的电解质和代谢异常，如高磷血症、高钾血症和低钙血症。TLS通常发生于侵袭性血液系统恶性肿瘤，如伯基特淋巴瘤和急性白血病。在多发性骨髓瘤（MM）中很少观察到TLS。
我们报告2例复发MM患者，在接受卡非佐米治疗的第一个周期后发生了TLS。
卡非佐米是一种新一代蛋白酶体抑制剂，在复发/难治性MM中已证实有效。最近，MM中TLS的发生频率有所增加，尤其是在使用蛋白酶体抑制剂治疗后。特别是在卡非佐米治疗的第一个周期，应考虑TLS的潜在并发症。
